Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP537545.RAJZp4WWRVdjhRxLCTP2plQQMi02sPJriB4YdXPOy5kW0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP537545.RAJZp4WWRVdjhRxLCTP2plQQMi02sPJriB4YdXPOy5kW0130_assertion type Assertion NP537545.RAJZp4WWRVdjhRxLCTP2plQQMi02sPJriB4YdXPOy5kW0130_head.
- NP537545.RAJZp4WWRVdjhRxLCTP2plQQMi02sPJriB4YdXPOy5kW0130_assertion description "[The use of reverse-transcription polymerase chain reaction (RT-PCR) for the detection of the PML-RARA and RARA-PML fusion genes is the only technique that defines the PML breakpoint type and that allows the definition of a correct strategy for subsequent minimal residual disease (MRD) monitoring.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP537545.RAJZp4WWRVdjhRxLCTP2plQQMi02sPJriB4YdXPOy5kW0130_provenance.
- NP537545.RAJZp4WWRVdjhRxLCTP2plQQMi02sPJriB4YdXPOy5kW0130_assertion evidence source_evidence_literature NP537545.RAJZp4WWRVdjhRxLCTP2plQQMi02sPJriB4YdXPOy5kW0130_provenance.
- NP537545.RAJZp4WWRVdjhRxLCTP2plQQMi02sPJriB4YdXPOy5kW0130_assertion SIO_000772 16502581 NP537545.RAJZp4WWRVdjhRxLCTP2plQQMi02sPJriB4YdXPOy5kW0130_provenance.
- NP537545.RAJZp4WWRVdjhRxLCTP2plQQMi02sPJriB4YdXPOy5kW0130_assertion wasDerivedFrom befree-2016 NP537545.RAJZp4WWRVdjhRxLCTP2plQQMi02sPJriB4YdXPOy5kW0130_provenance.
- NP537545.RAJZp4WWRVdjhRxLCTP2plQQMi02sPJriB4YdXPOy5kW0130_assertion wasGeneratedBy ECO_0000203 NP537545.RAJZp4WWRVdjhRxLCTP2plQQMi02sPJriB4YdXPOy5kW0130_provenance.